SCHEMBL2200824

SCHEMBL2200824

CCOC(=O)c1c(-c2ccncc2)nn(-c2cccc(OC(F)(F)F)c2)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 4/20 0.47
PDE4B Q07343 1/20 0.47
NPSR1 Q6W5P4 2/20 0.47
MAPK1 P28482 1/20 0.47
ALDH1A1 P00352 3/20 0.46
SCN9A Q15858 2/20 0.44
SLC34A1 Q06495 1/20 0.42
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42
NPY5R Q15761 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ELANE P08246 2/20 0.41
CLK2 P49760 1/20 0.41
DYRK1A Q13627 1/20 0.41
HASPIN Q8TF76 1/20 0.41
SLC5A1 P13866 1/20 0.40
KDM4E B2RXH2 1/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2202525 0.89 PDE4D (0.47) PDE4DPDE4BNPSR1ALDH1A1SCN9A
SCHEMBL2201646 0.89 MEN1 (0.56) NPSR1MAPK1ALDH1A1SCN9AROCK2
SCHEMBL2198107 0.88 MAPT (0.50) PDE4DPDE4BNPSR1MAPK1ALDH1A1
SCHEMBL2200842 0.88 NPSR1 (0.43) NPSR1MAPK1ALDH1A1SCN9ASLC34A1
SCHEMBL2199384 0.84 PDE4D (0.67) PDE4DPDE4BNPSR1ALDH1A1SLC34A1
SCHEMBL2200720 0.79 ALDH1A1 (0.49) PDE4DPDE4BNPSR1ALDH1A1SCN9A
SCHEMBL3695155 0.78 CYP2C9 (0.42) NPSR1SCN9AKMT2ASLC5A1
SCHEMBL2201990 0.78 MEN1 (0.52) NPSR1ALDH1A1SCN9ANPY5RMEN1
SCHEMBL2201758 0.78 SCN9A (0.42) PDE4DPDE4BNPSR1ALDH1A1SCN9A
SCHEMBL2200296 0.78 MAPT (0.46) NPSR1MAPK1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
EP-2182953-A2 NEW PYRAZOL DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-12 EP disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 PDE4D 814/4885PDE4B 607/4885NPSR1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.